Hospital Pharmacy - May 2017 - 356

356
any nongynecological solid tumor. The study also had a larger
patient population (N = 143) than our study, with 3 different
cisplatin dosing groups assessed. Another key difference was a
standard mannitol regimen in which all doses were the same
compared with community-based dosing dependent on physician preference. Unfortunately, our study focused primarily on
mannitol prescribing practices and therefore could not control
the many confounders affecting cisplatin-induced AKI.
Despite several retrospective studies and limited randomized studies, the effect of mannitol on preventing cisplatininduced nephrotoxicity remains unclear. Given cisplatin's
widespread utility in the oncology world, reliable evidencebased guidelines for preventing cisplatin-induced nephrotoxicity are needed. Prospective research should be considered a
top priority to better address this concern.

Conclusion
A pharmacist-led newsletter intervention to educate prescribers appeared to change prescribing practices of mannitol. No
risk factors were identified, including mannitol use, for cisplatin-induced nephrotoxicity. Randomized trials are needed
to truly assess any benefit from mannitol use in patients
receiving cisplatin.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect
to the research, authorship, and/or publication of this article.

Funding
The author(s) received no financial support for the research, authorship, and/or publication of this article.

Hospital Pharmacy 52(5)
References
1. Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin
nephrotoxicity: a review. Am J Med Sci. 2007;334:
115-124.
2. Platinol [package insert]. Princeton, NJ: Bristol-Myers Squibb;
2010.
3. Mannitol [package insert]. Lake Forest, IL: Hospira; 2009.
4. Santoso J, Lucci J, Coleman R, et al. Saline, mannitol,
and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol.
2003;52:13-18.
5. Al-Sarraf M, Fletcher W, Oishi N, et al. Cisplatin hydration
with and without mannitol diuresis in refractory disseminated
malignant melanoma: a Southwest Oncology Group Study.
Cancer Treat Rep. 1982;66(1):31-35.
6. Leu L, Baribeault D. A comparison in the rates of cisplatin-
induced nephrotoxicity associated with sodium loading or
sodium loading with forced diuresis as a preventative measure.
J Oncol Pharm Pract. 2010;16:167-171.
7. Morgan KP, Buie LW, Savage SW. The role of mannitol as
a nephroprotectant in patients receiving cisplatin therapy. Ann
Pharmacother. 2012;46:276-281.
8. Department of Health and Human Services. National Cancer
Institute. Common Terminology Criteria for Adverse Events
(CTCAE), Version 4.0. NIH Publication no. #09-7473.
Published May 29, 2009. https://evs.nci.nih.gov/ftp1/CTCAE/
CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf.
Accessed June 6, 2017.
9. Winder M, Johnson J, Planas L, et al. Impact of pharmacist-led
educational and error notification interventions on prescribing errors in a family medicine clinic. J Am Pharm Assoc.
2015;55(3):238-245.
10. Morgan K, Snavely AC, Wind LS, et al. Rates of renal toxicity
in cancer patients receiving cisplatin with and without mannitol. Ann Pharmacother. 2014;48(7):863-869.

https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf

Table of Contents for the Digital Edition of Hospital Pharmacy - May 2017